EcoDrugPlus

Endothelin B Receptor-Like

Ensembl ID : ENSAPOG00000005590
Gene Symbol: LOC110964723
3 Cross references
201 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSAPOG00000012247
Gene Symbol: ECE1
3 Cross references
231 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSAPOG00000019850
Gene Symbol: EDNRA
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSAPOG00000020875
Gene Symbol: EDNRB
3 Cross references
178 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSAPOG00000022331
Gene Symbol: EDNRB
3 Cross references
200 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSAPOG00000001967
Gene Symbol: EZH2
3 Cross references
240 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSAPOG00000013926
Gene Symbol: EGFRA
1 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2

Ensembl ID : ENSAPOG00000022494
Gene Symbol: EPHX2
3 Cross references
204 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSAPOG00000005289
Gene Symbol: LOC110964064
3 Cross references
204 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSAPOG00000022725
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSAPOG00000015464
Gene Symbol: ERBB3
3 Cross references
209 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSAPOG00000011865
Gene Symbol: ERBB4
4 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).